IP Library Granted Patent US 10,125,186
Granted Patent B2
US 10,125,186 · App. 15/340,195 · Granted Nov 13, 2018

Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,125,186
App. No.
15/340,195
Granted
Nov 13, 2018
Kind
B2
Abstract

Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.

Claims (47)

1. A nucleic acid capable of encoding a single chain antibody comprising a human variable light chain framework (VL) and a human variable heavy chain framework (VH) having the general structure:

NH 2 —VL-linker-VH—COOH, or

NH 2 —VH-linker-VL-COOH

wherein the single-chain antibody has the VH framework and the VL framework of

AK, BK, CK, DK, EK, FK, or GK:

wherein A is the amino acid sequence (Seq. Id. No. 1)

EIVMTQSPSTLSASVGDRVIITCRASQSISSWLAWYQQKPGKAPKLLIYK

ASSLESGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQQYKSYWTFGQG

TKLTVLG;

B is the amino acid sequence (Seq. Id. No. 2)

EIVLTQSPSSLSASVGDRVILTCRASQGIRNELAWYQQRPGKAPKRLIYA

GSILQSGVPSRFSGSGSGTEFTLTISSLQPEDVAVYYCQQYYSLPYMFGQ

GTKVDIKR;

C is the amino acid sequence (Seq. Id. No. 3)

EIVMTQSPATLSVSPGESAALSCRASQGVSTNVAWYQQKPGQAPRLLIYG

ATTRASGVPARFSGSGSGTEFTLTINSLQSEDFAAYYCQQYKHWPPWTFG

QGTKVEIKR;

D is the amino acid sequence (Seq. Id. No. 4)

QSVLTQPPSVSAAPGQKVTISCSGSTSNIGDNYVSWYQQLPGTAPQLLIY

DNTKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSGVV

FGGGTKLTVLG;

E is the amino acid sequence (Seq. Id. No. 5)

EIVLTQSPATLSLSPGERATLSCRASQTLTHYLAWYQQKPGQAPRLLIYD

TSKRATGVPARFSGSGSGTDFTLTISSLEPEDSALYYCQQRNSWPHTFGG

GTKLEIKR;

F is the amino acid sequence (Seq. Id. No. 6)

SYVLTQPPSVSVAPGQTATVTCGGNNIGSKSVHWYQQKPGQAPVLVVYDD

SDRPSGIPERFSGSNSGNTATLTIRRVEAGDEADYYCQVWDSSSDHNVFG

SGTKVEIKR;

G is the amino acid sequence (Seq. Id. No. 7)

LPVLTQPPSVSVAPGQTARISCGGNNIETISVHWYQQKPGQAPVLVVSDD

SVRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDYVVFG

GGTKLTVLG;

and

K is the amino acid sequence (Seq. Id. No. 11)

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSA

ISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDA

GIAVAGTGFDYWGQGTLVTVSS.

2. A vector comprising the nucleic acid according to claim 1 .

3. A host cell comprising the nucleic acid according to claim 1 .

4. The nucleic acid of claim 1 , wherein orientation of the VH and VL regions of the single chain antibody is reversed.

5. The nucleic acid of claim 1 , wherein the VL domain has the framework sequence of SEQ ID NO: 1 and the VH domain has the framework sequence of SEQ ID NO: 11.

6. A vector comprising the nucleic acid according to claim 5 .

7. A host cell comprising the nucleic acid according to claim 5 .

8. The nucleic acid of claim 1 , wherein the single-chain antibody comprises a variant of the VL framework sequence of SEQ ID NO: 1 and a variant of the VH framework sequence of SEQ ID NO: 11.

9. A vector comprising the nucleic acid according to claim 8 .

10. A host cell comprising the nucleic acid according to claim 8 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2024
From: ESBATECH, A NOVARTIS COMPANY LLC
To: NOVARTIS AG
Reel/Frame 066375/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: TISSOT, KATHRIN; EWERT, STEFAN; AUF DER MAUR, ADRIAN; BARBERIS, ALCIDE; ESCHER, DOMINIK
To: ESBATECH AG
Reel/Frame 047767/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2018
From: ESBATECH, A NOVARTIS COMPANY LLC
To: NOVARTIS AG
Reel/Frame 047768/0136 →